RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway

Circulation Research - Tập 104 Số 9 - Trang 1041-1048 - 2009
Sara Panizo1, Anna Cardús1,2,3, Mario Encinas1,2,3, Eva Parisi1,4, Petya Valcheva1,4, Susana López‐Ongil1,2,3, Blai Coll1,2,3, Elvira Fernández1,2,3, José Manuel Valdivielso1,2,3
1From the Department of Medicine (S.P., A.C., E.P., P.V.), University of Lleida; Research Laboratory (S.P., A.C., M.E., E.P., P.V., J.M.V.), Hospital Universitari Arnau de Vilanova; Research Unit and Nephrology Section (S.L.-O.), Hospital Universitario Príncipe de Asturias, Alcala de Henares, Madrid; and Unitat de Diagnòstic i Tractament de Malaties Aterotrombòtiques (UDETMA) (B.C., E.F., J.M.V.), Nephrology Department, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de...
2Unitat de Diagno `stic i Tractament de Malaties Aterotrombo `tiques (UDETMA)
3University of Lleida; Research Laboratory (S.
4LIPPINCOTT WILLIAMS & WILKINS

Tóm tắt

Vascular calcification commonly associated with several pathologies and it has been suggested to be similar to bone mineralization. The axis RANKL-OPG (receptor activator of nuclear factor κB ligand–osteoprotegerin) finely controls bone turnover. RANKL has been suggested to increase vascular calcification, but direct evidence is missing. Thus, in the present work, we assess the effect of RANKL in vascular smooth muscle cell (VSMC) calcification. VSMCs incubated with RANKL showed a dose-dependent increase in calcification, which was abolished by coincubation with OPG. To test whether the effect was mediated by signaling to its receptor, knockdown of RANK was accomplished by short hairpin (sh)RNA. Indeed, cells lacking RANK showed no increases in vascular calcification when incubated with RANKL. To further elucidate the mechanism by which RANK activation increases calcification, we blocked both nuclear factor (NF)-κB activation pathways. Only IKKα inactivation inhibited calcification, pointing to an involvement of the alternative NF-κB activation pathway. Furthermore, RANKL addition increased bone morphogenetic protein (BMP)4 expression in VSMCs, and that increase disappeared in cells lacking RANK or IKKα. The increase in calcification was also blunted by Noggin, pointing to a mediation of BMP4 in the calcification induced by RANKL. Furthermore, in an in vivo model, the increase in vascular calcium content was parallel to an increase in RANKL and BMP4 expression, which was localized in calcified areas. However, blood levels of the ratio RANKL/OPG did not change. We conclude that RANKL increases vascular smooth muscle cell calcification by binding to RANK and increasing BMP4 production through activation of the alternative NF-κB pathway.

Từ khóa


Tài liệu tham khảo

10.1152/ajpendo.00552.2003

10.1097/01.mnh.0000168336.67499.c0

Detrano RC, Doherty TM, Davies MJ, Stary HC. Predicting coronary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol. 2000; 25: 374–402.

10.1161/hyp.38.4.938

10.1073/pnas.1932554100

10.1038/nature01654

10.1001/jama.292.4.490

10.1016/S0092-8674(00)81569-X

10.1073/pnas.96.7.3540

10.1016/S0092-8674(00)80209-3

10.1007/s001090100226

10.1101/gad.12.9.1260

10.1161/atvb.21.12.1998

10.1084/jem.192.4.463

10.1038/sj.ki.5000304

10.1359/jbmr.070305

10.1074/jbc.M601350200

10.1152/ajpregu.1999.276.6.R1718

10.1159/000092198

10.1161/01.atv.0000012303.37971.da

Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004; 74: 103–106.

10.1016/j.yjmcc.2003.09.015

10.1161/atvb.21.10.1610

10.1161/circulationaha.107.707380

10.1016/S0140-6736(01)05494-0

10.1161/01.ATV.21.5.817

10.1093/ndt/gfh263

10.1074/jbc.273.23.14363

10.1006/bbrc.2000.4130

10.1152/ajplung.2000.278.5.L1045

10.1097/01.ASN.0000141960.01035.28

10.1074/jbc.M406392200

10.1084/jem.20030116

10.1196/annals.1346.003

10.1128/MCB.00759-06

10.1007/s00223-007-9073-6

10.1161/01.res.0000161997.24797.c0

10.1161/circ.100.21.2168

10.1161/01.cir.0000127957.43874.bb

10.1210/jc.2002-020775

10.1097/01.CCM.0000190429.52746.33

10.1001/jama.291.9.1108

10.1161/01.cir.0000060815.25798.02

10.1161/CIRCULATIONAHA.106.686774